<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83763">
  <stage>Registered</stage>
  <submitdate>27/03/2009</submitdate>
  <approvaldate>30/04/2009</approvaldate>
  <actrnumber>ACTRN12609000218291</actrnumber>
  <trial_identification>
    <studytitle>Influence of Race/Ethnic Origin on the breakdown/elimination of SCH 527123 in the body.</studytitle>
    <scientifictitle>Influence of Race/Ethnic Origin on the Pharmacokinetics of SCH 527123 (in Healthy Volunteers).</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil Known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>The Influence of race and ethnic origin on the pharmacokinetics of SCH 527123.</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Part 1: SCH 527123 10mg, 30mg, 50mg single oral dose on Day 1 (Each subject receives all 3 doses in a randomised sequence, separated by at least 7 days before progressing to part 2 of the study).
Part 2: SCH 527123 10mg or 50mg daily for 7 days (Randomised to receive one or the other dose level)</interventions>
    <comparator>N/A</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the influence of race and ethnic origin on the pharmacokinetics of SCH 527123.
(Assessed through comparison of pharmacokinetic (PK) data from blood samples  between Japanese, Chinese and Caucasian subjects)</outcome>
      <timepoint>Assessed on Days 1-4 for each period of Part 1 of the study and on Days 1 &amp; 6-10 in Part 2 of the study.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the pharmacodynamics, safety &amp; tolerability of SCH 527123 in Healthy Subjects. (Assessed via peripheral blood neutrophil counts and Flourescence-Activated Cell Sorter (FACS) analysis &amp; routine laboratory safety tests (haematology/chemistry &amp; urinalysis)).</outcome>
      <timepoint>Assessed throughout the study at Days 1-4 for each period of Part 1 and Days 1&amp; 6-10 for Part 2.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Parts 1 &amp; 2
- Male/Female Healthy volunteers (must be Caucasian, Japanese or Chinese)
- Caucasian &amp; Chinese volunteers must match Japanese volunteers for sex, age, height, weight, Body Mass Index (BMI) within specified ranges.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>History of malignancy, Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C, Neutrophil count of &lt;2 x 10 9.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Open Label Study. Eligible Japanese subjects assigned a allocation number sequentially. Caucasian and Chinese subjects matched to Japanese subjects by age, weight, height, gender &amp; BMI and allocated to a corresponding allocation number with the same treatment sequence.</concealment>
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/06/2009</anticipatedstartdate>
    <actualstartdate>7/07/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>19/04/2010</actualenddate>
    <samplesize>32</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Schering-Plough</primarysponsorname>
    <primarysponsoraddress>2000 Galloping Hill Road
Kenilworth, New Jersey 07033</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Schering-Plough</fundingname>
      <fundingaddress>2000 Galloping Hill Road
Kenilworth, New Jersey 07033</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Demographic variables such as age, sex, race and body weight as well as genetic, environmental and cultural factors (eg, diet) may influence the safety &amp; therapeutic response to drugs. Therefore, this study aims to investigate these differences in Japanese, Chinese and Caucasian subjects.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>27/02/2009</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Peter Hodsman</name>
      <address>Centre For Clinical Studies
5th Floor Burnet Tower
AMREP Precinct
89 Commercial Road
Melbourne, VIC 3004</address>
      <phone>+61 3 9076 8960</phone>
      <fax />
      <email>p.hodsman@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Mary Franich</name>
      <address>Centre For Clinical Studies
5th Floor Burnet Tower
AMREP Precinct
89 Commercial Road
Melbourne, VIC 3004</address>
      <phone>1800 243 733</phone>
      <fax />
      <email>m.franich@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Andreane Laforest</name>
      <address>Schering-Plough
Level 4, 66 Waterloo Road
North Ryde, NSW 2113</address>
      <phone>+61 2 8988 8122</phone>
      <fax />
      <email>andreane.laforest@spcorp.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Peter Hodsman</name>
      <address>Centre For Clinical Studies 5th Floor Burnet Tower AMREP Precinct 89 Commercial Road Melbourne, VIC 3004  </address>
      <phone>+61 3 9076 8960</phone>
      <fax />
      <email>p.hodsman@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>